Home    Back

Vatelizumab    (DrugBank: Vatelizumab)

2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica6
97Ulcerative colitis10

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2014-001643-20-SE
(EUCTR)		03/07/201519/01/2015Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Nervous System Diseases
MedDRA version: 17.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		168Phase 2Germany;Italy;Switzerland;Sweden;United States;Czech Republic;Mexico;Canada;Poland;Russian Federation
2EUCTR2014-003265-19-PL
(EUCTR)		12/05/201526/02/2015Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839 Relapsing-remitting multiple sclerosis
MedDRA version: 18.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		168Phase 2United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
3EUCTR2014-001643-20-DE
(EUCTR)		10/02/201518/08/2014Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Nervous System Diseases
MedDRA version: 18.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		168Phase 2United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
4NCT02306811
(ClinicalTrials.gov)		February 20151/12/2014Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839Relapsing-remitting Multiple SclerosisDrug: VatelizumabGenzyme, a Sanofi CompanyNULLTerminated18 YearsN/ABoth62Phase 2United States;Canada;Poland;Russian Federation
5EUCTR2014-001643-20-PL
(EUCTR)		23/01/201531/10/2014Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Nervous System Diseases
MedDRA version: 18.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500		Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes		168Phase 2United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT02222948
(ClinicalTrials.gov)		September 201420/8/2014Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)Relapsing-remitting Multiple SclerosisDrug: Vatelizumab;Drug: Placebo (for Vatelizumab)Genzyme, a Sanofi CompanyNULLTerminated18 Years55 YearsBoth112Phase 2United States;Canada;Poland;Russian Federation;Sweden

Back to top


97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
10 / 2,269 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2013-001012-30-DE
(EUCTR)		20/01/201407/10/2013Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC) Ulcerative Colitis
MedDRA version: 16.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: SAR339658		Sanofi-aventis recherche & développementNULLNot RecruitingFemale: yes
Male: yes		80United States;Canada;Poland;Belgium;Austria;Germany;Italy
2EUCTR2013-001012-30-PL
(EUCTR)		17/10/201305/09/2013Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC) Ulcerative Colitis
MedDRA version: 16.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: SAR339658		Sanofi-aventis recherche & développementNULLNot RecruitingFemale: yes
Male: yes		80United States;Canada;Poland;Austria;Germany;Italy
3EUCTR2013-001012-30-BE
(EUCTR)		09/10/201312/08/2013Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC) Ulcerative Colitis
MedDRA version: 16.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: SAR339658		Sanofi-aventis recherche & développementNULLNot RecruitingFemale: yes
Male: yes		80Phase 2United States;Canada;Poland;Belgium;Austria;Germany;Italy
4EUCTR2013-001012-30-IT
(EUCTR)		30/09/201302/07/2013Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC) Ulcerative Colitis
MedDRA version: 16.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: SAR339658		Sanofi-aventis recherche & développementNULLNot RecruitingFemale: yes
Male: yes		80United States;Canada;Poland;Austria;Germany;Italy
5EUCTR2012-002013-19-DE
(EUCTR)		25/09/201317/05/2013Efficacy and Safety of SAR339658 in Patients with Moderate to Severe Ulcerative ColitisA randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC). - FUSCIA Ulcerative Colitis
MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab		Sanofi aventis Recherche&DéveloppementNULLNot RecruitingFemale: yes
Male: yes		93France;United States;Canada;Belgium;Poland;Austria;Germany;Italy
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2012-002013-19-PL
(EUCTR)		12/09/201314/06/2013Efficacy and Safety of SAR339658 in Patients with Moderate to Severe Ulcerative ColitisA randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC). - FUSCIA Ulcerative Colitis
MedDRA version: 16.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab		Sanofi aventis Recherche&DéveloppementNULLNot RecruitingFemale: yes
Male: yes		93France;United States;Canada;Belgium;Poland;Austria;Germany;Italy
7EUCTR2013-001012-30-AT
(EUCTR)		04/09/201312/07/2013Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC) Ulcerative Colitis
MedDRA version: 16.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: SAR339658		Sanofi-aventis recherche & développementNULLNot RecruitingFemale: yes
Male: yes		80United States;Canada;Poland;Austria;Germany;Italy
8EUCTR2012-002013-19-BE
(EUCTR)		19/07/201319/02/2013Efficacy and Safety of SAR339658 in Patients with Moderate to Severe Ulcerative ColitisA randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC). - FUSCIA Ulcerative Colitis
MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab		Sanofi aventis Recherche&DéveloppementNULLNot RecruitingFemale: yes
Male: yes		93Phase 2France;United States;Canada;Poland;Belgium;Austria;Germany;Italy
9EUCTR2012-002013-19-IT
(EUCTR)		02/06/201308/04/2013Efficacy and Safety of SAR339658 in Patients with Moderate to Severe Ulcerative ColitisA randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC). - FUSCIA Ulcerative Colitis
MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab		Sanofi aventis Recherche&DéveloppementNULLNot RecruitingFemale: yes
Male: yes		93United States;France;Canada;Poland;Belgium;Austria;Germany;Italy
10EUCTR2012-002013-19-AT
(EUCTR)		16/04/201321/03/2013Efficacy and Safety of SAR339658 in Patients with Moderate to Severe Ulcerative ColitisA randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC). - FUSCIA Ulcerative Colitis
MedDRA version: 16.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Product Code: SAR339658
INN or Proposed INN: Vatelizumab		Sanofi aventis Recherche&DéveloppementNULLNot RecruitingFemale: yes
Male: yes		93France;United States;Canada;Belgium;Poland;Austria;Germany;Italy

Back to top